SCHEMBL1619192

SCHEMBL1619192

[C]#CCC#C[CH2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769845 0.69
SCHEMBL8991796 0.69
SCHEMBL8769966 0.66
SCHEMBL8769433 0.65
SCHEMBL8991794 0.65
SCHEMBL270282 0.64
SCHEMBL43047 0.64
SCHEMBL8769405 0.62
SCHEMBL5986157 0.62
SCHEMBL8769394 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024149093-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-07-18 WO disclosed
WO-2024114531-A1 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 WO disclosed
WO-2024114523-A1 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 WO disclosed
WO-2024114318-A1 DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 WO disclosed
US-7994346-B2 such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-09 US disclosed
US-7928255-B2 Intermediates for the preparation of lipoxin A4 analogs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-04-19 US disclosed
EP-2056816-A2 LIPOXIN A4 ANALOGS FOR THE TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-05-13 EP disclosed
EP-1472209-B1 LIPOXIN A4 ANALOGS BAYER SCHERING PHARMA AG (DE) 2009-03-04 EP disclosed
US-20080119439-A1 Treatment and prevention of intestinal fibrosis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2008-05-22 US disclosed
WO-2008022807-A2 LIPOXIN A4 ANALOGS FOR THE TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-28 WO disclosed
US-20070105949-A1 Intermediates for the preparation of lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-10 US disclosed
US-20070037864-A1 Intermediates for the preparation of lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2007-02-15 US disclosed
US-6831186-B2 Antiinflammatory agents; autoimmune disease SCHERING AKTIENGESELLSCHFT (DE) 2004-12-14 US disclosed
EP-1472209-A2 LIPOXIN A4 ANALOGS SCHERING AKTIENGESELLSCHAFT (DE) 2004-11-03 EP disclosed
US-20040162433-A1 Lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2004-08-19 US disclosed
US-20030139376-A1 Lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-24 US disclosed
WO-2003040080-A2 LIPOXIN A4 ANALOGS SCHERING AKTIENGESELLSCHAFT (DE) 2003-05-15 WO disclosed
EP-0570594-B1 HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE SHIONOGI & CO (JP) 1997-07-30 EP disclosed
US-5534654-A ANTITUMOR, ANTIINFLAMMATORY, INHIBITOR OF LYMPHOCYTE ADHESIVE FACTORS SHIONOGI & CO., LTD. (JP) 1996-07-09 US disclosed
EP-0570594-A1 HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE SHIONOGI & CO., LTD. (JP) 1993-11-24 EP disclosed